Use of chimeric Anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant

a technology of chimeric anti-cd20 and purging agent, which is applied in the field of anti-cd20 antibody, can solve the problems of often subjected to disease relapse in treated patients, and achieve the effect of reducing the incidence of disease relaps

Inactive Publication Date: 2011-07-07
BIOGEN INC
View PDF61 Cites 64 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]More specifically, it is an object of the invention to reduce the incidence of disease relapse in patients with B-cell-related diseases receiving bone marrow or peripheral blood stem cell transplants by the use of an anti-CD20 antibody as an in vitro and / or in vivo purging agent prior, concurrent, and / or after transplant.

Problems solved by technology

However, while anti-CD20 antibodies and, in particular, RITUXAN®, have been reported to be effective for treatment of B-cell lymphomas, such as non-Hodgkin's lymphoma, the treated patients are often subject to disease relapse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example

[0033]A single-arm pivotal study of rituximab infused at 375 mg / m2 weekly times four was conducted in 166 patients with relapsed or refractory, low-grade or follicular NHL (International Working Formulation [IWF] Types A-D and REAL classification, small lymphocytic lymphoma, Follicular center, follicular Grades I, II, III). (McLaughlin P, Grillo-López A, Link B, Levy R, Czuczman M, Williams M, Heyman M, Bence-Bruckler I, White C, Cabanillas F, Jain V, Ho A, Lister J, Wey K, Shen D, Dallaire B. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. Journal of Clinical Oncology 1998; 16:2825-2833.) Patients with tumor masses >10 cm or with >5000 lymphocytes / μL in the peripheral blood were excluded from this study. The median age was 58 years (105 men and 61 women) and the median number of prior treatments was three. Bone marrow involvement was present in 56% of 149 patients evaluated. Forty-five ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
median timeaaaaaaaaaa
median timeaaaaaaaaaa
densitiesaaaaaaaaaa
Login to view more

Abstract

The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and / or prevent disease relapse in such patients.

Description

RELATED APPLICATIONS[0001]This application is a continuation of pending application Ser. No. 12 / 100,303, filed 9 Apr. 2008; which is a continuation of application Ser. No. 10 / 850,712, filed 21 May 2004, now abandoned; which is a divisional of application Ser. No. 09 / 436,348, filed 9 Nov. 1999, now abandoned; which claims priority under 35 U.S.C. §119(e) to U.S. provisional application Ser. No. 60 / 107,657, filed 9 Nov. 1998, now lapsed; the entire contents of each of which is incorporated by reference herein.FIELD OF THE INVENTION[0002]The use of an anti-CD20 antibody or a fragment thereof as an in vitro or in vivo purging agent in patients receiving bone marrow transplant or peripheral blood stem cell transplant is disclosed.BACKGROUND OF THE INVENTION[0003]The use of antibodies to the CD20 antigen as diagnostic and / or therapeutic agents for B-cell lymphoma has previously been reported. CD20 is a useful marker or target for B-cell lymphomas as this antigen is expressed at very high ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00A61P35/02A61P37/06C07K16/28
CPCA61K2039/505C07K16/2887C07K2317/76A61K39/3955C07K2317/24A61P35/00A61P35/02A61P37/00A61P37/06A61K39/395
Inventor GRILLO-LOPEZ, ANTONIO J.LEONARD, JOHN
Owner BIOGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap